CA3251231A1 - Variants of protein Z binding to thymic stromal lymphopoietin and their medical use - Google Patents
Variants of protein Z binding to thymic stromal lymphopoietin and their medical useInfo
- Publication number
- CA3251231A1 CA3251231A1 CA3251231A CA3251231A CA3251231A1 CA 3251231 A1 CA3251231 A1 CA 3251231A1 CA 3251231 A CA3251231 A CA 3251231A CA 3251231 A CA3251231 A CA 3251231A CA 3251231 A1 CA3251231 A1 CA 3251231A1
- Authority
- CA
- Canada
- Prior art keywords
- tslp
- seq
- sequence
- binding
- binding polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22155646 | 2022-02-08 | ||
| EP22155646.7 | 2022-02-08 | ||
| PCT/EP2023/053030 WO2023152144A1 (en) | 2022-02-08 | 2023-02-08 | Protein z variants binding thymic stromal lymphopoietin and their medical use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3251231A1 true CA3251231A1 (en) | 2023-08-17 |
Family
ID=80682629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3251231A Pending CA3251231A1 (en) | 2022-02-08 | 2023-02-08 | Variants of protein Z binding to thymic stromal lymphopoietin and their medical use |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4476247A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025506381A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240139058A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118632866A (cg-RX-API-DMAC7.html) |
| AR (1) | AR128475A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023218534A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3251231A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL314458A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024009732A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023152144A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE08786222T1 (de) | 2007-07-31 | 2010-11-25 | Affibody Ab | Neue albuminbindende zusammensetzungen, verfahren und anwendungen |
| ES2373832T3 (es) | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| BR112013000452A2 (pt) | 2010-07-09 | 2020-02-11 | Affibody Ab | Polipeptídeo de ligação de albumina, proteína de fusão ou conjugado, polinucleotídeo, método para produzir um polipeptídeo, composição, método para a preparação de uma composição, e, método para aumentar a solubilidade de um composto |
| US10155792B2 (en) | 2012-09-25 | 2018-12-18 | Affibody Ab | Albumin binding polypeptide |
| WO2015189430A1 (en) | 2014-06-13 | 2015-12-17 | Affibody Ab | New polypeptide |
| KR20240110106A (ko) * | 2015-01-12 | 2024-07-12 | 애피바디 에이비 | Il-17a-결합 폴리펩티드 |
| CA3001264A1 (en) | 2015-10-30 | 2017-05-04 | Affibody Ab | Pd-l1 binding polypeptide |
| WO2021089695A1 (en) * | 2019-11-05 | 2021-05-14 | Affibody Ab | Polypeptides |
-
2023
- 2023-02-08 MX MX2024009732A patent/MX2024009732A/es unknown
- 2023-02-08 WO PCT/EP2023/053030 patent/WO2023152144A1/en not_active Ceased
- 2023-02-08 JP JP2024545909A patent/JP2025506381A/ja active Pending
- 2023-02-08 EP EP23703451.7A patent/EP4476247A1/en active Pending
- 2023-02-08 KR KR1020247025767A patent/KR20240139058A/ko active Pending
- 2023-02-08 AR ARP230100294A patent/AR128475A1/es unknown
- 2023-02-08 AU AU2023218534A patent/AU2023218534A1/en active Pending
- 2023-02-08 CN CN202380019293.5A patent/CN118632866A/zh active Pending
- 2023-02-08 IL IL314458A patent/IL314458A/en unknown
- 2023-02-08 CA CA3251231A patent/CA3251231A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023218534A1 (en) | 2024-07-11 |
| CN118632866A (zh) | 2024-09-10 |
| AR128475A1 (es) | 2024-05-15 |
| WO2023152144A1 (en) | 2023-08-17 |
| KR20240139058A (ko) | 2024-09-20 |
| EP4476247A1 (en) | 2024-12-18 |
| MX2024009732A (es) | 2024-08-19 |
| IL314458A (en) | 2024-09-01 |
| JP2025506381A (ja) | 2025-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105555310B (zh) | 一种提高蛋白血清半衰期的组合物和方法 | |
| RU2749712C2 (ru) | IL-17A-связывающие полипептиды | |
| JP2013518853A (ja) | 血清アルブミンと結合することが可能なペプチド並びにこれを含む化合物、構築物及びポリペプチド | |
| KR20100098697A (ko) | 폐 전달을 위한 조성물 | |
| KR20140129163A (ko) | 인간 보체 c5에 결합하는 폴리펩티드 | |
| JP2010505435A (ja) | 本質的にpHに非依存的に血清タンパク質に結合するアミノ酸配列、それを含む化合物、およびその使用 | |
| TW201529601A (zh) | 人類抗il-33中和單株抗體 | |
| US20250066451A1 (en) | Il-ir-i binding polypeptide | |
| US10633423B2 (en) | IL-6-binding polypeptide complex | |
| CN106488930B (zh) | 新型多肽 | |
| CN121002060A (zh) | 犬il-13的犬抗体 | |
| AU2023218534A1 (en) | Protein z variants binding thymic stromal lymphopoietin and their medical use | |
| JP7754510B2 (ja) | 血清アルブミン結合ナノボディ組成物、及びその使用方法 | |
| US20220389066A1 (en) | Polypeptides | |
| WO2025223473A1 (zh) | 抗gdf-15抗体及其应用 | |
| CN121362254A (zh) | 抗IL-4Rα单域抗体、其融合蛋白、药物组合物及用途 | |
| CN118620057A (zh) | Il-1r1胞外区多肽突变体及其用途 | |
| HK1235298B (en) | New polypeptide | |
| HK1235298A1 (en) | New polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240806 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250113 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250113 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250114 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20250114 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250114 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250203 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250203 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250203 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260115 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260115 |